leadf
logo-loader
viewReNeuron Group PLC

Full interview: 'All systems go' for ReNeuron's retinitis pigmentosa programme as it looks to follow-up studies

ReNeuron Group PLC's (LON:RENE) Michael Hunt tells Proactive London's Andrew Scott they've seen a 'rapid and profound' result in the first three patients of the second phase of clinical studies of its human retinal progenitor cells (hRPC).

''What we're seeing is hugely encouraging and I think the principal investigator will make that clear when he presents the data next weekend''.

Quick facts: ReNeuron Group PLC

Price: 86.5 GBX

LSE:RENE
Market: LSE
Market Cap: £27.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

ReNeuron Group PLC: Proactive One2One Virtual Conference

ReNeuron Group PLC's (LON:RENE) Michael Hunt presents at the Proactive One2One Virtual Conference. ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

3 weeks, 1 day ago

2 min read